Erfonrilimab

依瑞利单抗

Report date: 2026/05/02 20:00:18

Base Information

Drug NameErfonrilimab
Drug Alias NameKN-046
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionCytotoxic T-Lymphocyte-Associated Antigen 4 inhibitorsProgrammed death-ligand 1 blockers
TargetsProgrammed death-ligand 1Cytotoxic T-Lymphocyte-Associated Antigen 4
Therapy Area/IndicationsSolid tumoursThymus NeoplasmsCarcinoma, Non-Small-Cell Lung +[18] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwanAustralia +[4] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesJiangsu Alphamab Biopharmaceuticals Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBeijing Cancer HospitalHangzhou Taibo Pharmaceutical Co LtdFudan University +[5] 
Inactive CompaniesWeill Medical College of Cornell UniversityAlphamab (Australia) Co Pty Ltd
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungPancreatic Neoplasms +[14] 
Inactive IndicationsThymus NeoplasmsCarcinoma, HepatocellularNeuroendocrine Tumors +[4] 

Other Information

ATC CodeN/A
Related LinksN/A